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Chondrocytes and adipocytes are two diﬀerentiated cell types which are both derived from mesenchymal cells. The purpose of
this study was to investigate whether peroxisome proliferator-activated receptor-γ (PPARγ), a transcription factor involved in
lineage determination during adipogenesis, is able to induce adipogenic diﬀerentiation in growth plate chondrocytes. Isolated
epiphyseal chondrocytes were infected with a PPARγ adenovirus or treated with the PPARγ agonist ciglitazone. Both of these
treatments resulted in lipid droplet accumulation and expression of the adipogenic markers aP2, lipoprotein lipase, and adipsin in
chondrocytes. Proteoglycan matrix synthesis was decreased in the PPARγ-infected cells, as was the expression of the chondrogenic
genes Col2a1 and aggrecan. Growth plate cells transfected with a PPARγ expression plasmid under the control of the collagen
α1(II)promoteralsodemonstratedasimilaradipogenicchanges.Terminaldiﬀerentiationofgrowthplatechondrocytesinducedby
thyroid hormone was also inhibited by overexpression of PPARγ and ciglitazone treatment, with decreased expression of alkaline
phosphatase and Runx2/Cbfa1 genes. These in vitro data suggest that PPARγ is able to promote adipogenic diﬀerentiation in
growth plate chondrocytes, while negatively regulating chondrogenic diﬀerentiation and terminal diﬀerentiation.
Copyright © 2006 Lai Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Longitudinal growth of the skeleton is a result of endochon-
dral ossiﬁcation that occurs at the growth plate [1]. En-
dochondral ossiﬁcation is a multistep process that includes
diﬀerentiation of mesenchymal cells into chondrocytes, cell
proliferation, hypertrophic diﬀerentiation, matrix mineral-
ization, apoptosis, vascular invasion, and eventually the re-
placement of the cartilage by bone.
The ﬁrst step of growth plate development is the com-
mitment of mesenchymal stem cells to the chondrogenic
lineage. Mesenchymal stem cells exhibit a high diﬀerentia-
tion plasticity. They are capable of diﬀerentiating into chon-
drocytes, osteoblasts, adipocytes, and other tissues of mes-
enchymal origin [2]. Interconversion between mesenchy-
mal phenotypes is thought to be under control of speciﬁc
transcription factors, including the Sox family in chondro-
genesis [3], Runx2/Cbfa1 in osteogenesis [4], and PPARγ
(peroxisome proliferator-activated receptor-γ), and C/EBP
(CCAAT/enhancer-binding protein) in adipogenesis [5].
PPARγ is a key transcriptional regulator of adipogene-
sis [5]. PPARγ is also expressed in preosteoblastic cells and
is thought to play a role in regulation of bone metabolism.
PPARγ and PPARγ activators inhibit the maturation of
preosteoblastic cells to osteoblasts [6–8]. Free fatty acids ac-
tivate PPARs and induce adipocyte-like diﬀerentiation of os-
teosarcoma cell lines [6]. Lecka-Czernik et al observed that
PPARγ2 negatively regulates stromal cell plasticity by sup-
pressing expression Osf2/Cbfa1 and osteoblast-like biosyn-
thetic activity, while promoting diﬀerentiation to adipocytes
[7]. Conversely, PPARγ insuﬃciency enhances osteogene-
sis through increased osteoblast formation from bone mar-
row progenitors. Homozygous PPARγ-deﬁcient ES cells fail
to diﬀerentiate into adipocytes, but increase bone mass by
stimulating osteoblastogenesis from bone marrow progeni-
tors [8].
Transdiﬀerentiation of chondrocytes to adipocytes has
been previously reported by Heermeier et al, who observed
that chondrocytes of the mouse xiphoid process undergo
transdiﬀerentiation into adipocytes in the presence of 10%
fetal calf serum [9].
Based on the ﬁnding that PPARγ is expressed in growth
plate chondrocytes [10], as well as the evidence that PPARγ
is able to compete with the thyroid hormone receptor (TR)
for binding to retinoic acid receptor X to inhibit growth
plate cell hypertrophy [11], the purpose of this study was to2 PPAR Research
investigate whether PPARγ and its ligands are able to pro-
mote adipogenic diﬀerentiation and suppress chondrogenic
diﬀerentiation in growth plate chondrocytes.
MATERIALS AND METHODS
Cellculture
Chondrocytes were isolated from the resting zone of the
distal femoral growth plate of 2-day old neonatal Sprague-
Dawley rats by sequential digestion in trypsin/EDTA (Invit-
rogen, Carlsbad, Calif) for 1 hour at 37◦C, followed by 0.3%
collagenase type I (Worthington, Lakewood, NJ) for 4 hours
at37◦C[12].CellswereresuspendedinDMEM/F12medium
(Invitrogen) supplemented with a deﬁned media supple-
ment (ITS+1, Sigma, St Louis, Mo) and plated in mono-
layer at a density of 5 × 105 cells/cm2,o ri nap e l l e tc u l -
ture of 1 × 105 cells/mL as indicated [12]. Tri-iodothyronine
(T3, Sigma) at a concentration of 100ng/mL and ciglitazone
(BioMol, Plymouth Meeting, Pa) at a concentration of 5μM
were added to the medium as indicated.
Immunoblotting
Total cellular protein was extracted from chondrocytes
treated with 5μM of ciglitazone using RIPA buﬀer [9].
An equal amount of protein was subjected to SDS-PAGE,
and transferred onto nitrocellulose membranes. The blots
were incubated with anti-PPARγ and anti-actin (Santa Cruz
Biotechnology, Santa Cruz, Calif) followed by a HRP-
conjugated secondary antibody. Immunoreactive proteins
were visualized by Western Blotting Chemiluminescence Lu-
minol Reagent (Santa Cruz Biotechnology). Immunoblot
bands were quantitated with Kodak 1D Image Analysis Soft-
ware (Eastman Kodak Company, Rochester, NY).
Adenovirusinfection
Recombinant adenovirus carrying PPARγ1 (Ad-PPARγ)w a s
kindly provided by Dr J. L. Jameson (Northwestern Univer-
sityMedicalSchool,Chicago,Ill).Ad-PPARγ containsmouse
PPARγ1 cDNA driven by the CMV promoter/enhancer with
an SV40 polyadenylation sequence [13]. Ad-Gal, which con-
tains β-galactosidase driven by CMV promoter, was used to
evaluate the eﬃciency of gene transduction. Eighteen hours
after plating in monolayer, growth plate chondrocytes were
infected with adenoviral vectors at a multiplicity of infection
(MOI) of 100. Fresh media were added 24 hours after infec-
tion and incubated for 72 hours to collect the cell protein
extracts. β-galactosidase expression was detected in 80% of
cells after 24 hours of infection with Ad-Gal. Expression of
introduced PPARγ genes was conﬁrmed by immunoblot.
Plasmidconstructionandtransienttransfection
The full-length cDNA of mouse PPARγ was excised by
Asp718/NheI digestionfrompCMX-PPARγ (kindlyprovided
byDrR.Evans,SalkInstitute,LaJolla,Calif).Theendsofthis
fragment were blunted with Klenow polymerase and ligated
to a blunt-ended BamHI site in the p1757 plasmid contain-
ing the rat α1(II) collagen promoter (kindly provided by Dr
Y. Yamada, NIDR, Bethesda, Md) [14]. The cDNA encod-
ing the mouse PPARγ was thus located downstream of the
rat α1 (II) collagen promoter element (−977 to +110). Nu-
cleotide sequence analysis conﬁrmed the correct orientation
of the PPARγ cDNA.
Growth plate cells were transfected with 10μg of p1757-
PPARγ or p1757 as a negative control by lipofection (Fugene
6, Roche, Indianapolis, Ind) in the presence of 4units/mL of
hyaluronidase. Sixteen hours later, the cells were trypsinized
and centrifuged to pellets cultured in DMEM/F12 plus ITS+
supplements [11].
Histochemicalstaining
For the analysis of adipogenic diﬀerentiation, adipoge-
nesis and lipid accumulation in the growth plate cells
were examined by staining with Oil Red-O. After 10 days
of culture, cells were washed gently with PBS followed
by staining with a ﬁltered solution of 0.5% Oil Red-O
(Sigma) in 60% isopropanol for 20 minutes. After wash-
i n gc e l l sw i t hP B St h r e et i m e s ,c e l l sw e r ek e p ti n7 5 %g l y c -
erol solution and observed under a phase-contrast micro-
scope.
Alcian blue staining was used to detect chondrocyte-
speciﬁcproteoglycansat10daysofculture.Cellswerestained
with a 4 : 1 ratio of 0.1M HCl/0.5% Alcian blue stock (0.5%
Alcian blue in 95% ethanol) overnight at 37◦C in a humidi-
ﬁed atmosphere. Cells were then washed twice with PBS to
stop reaction and once with 70% ethanol to reduce back-
ground.
For alkaline phosphatase (ALP) staining, cultured plates
were rinsed with PBS at 10 days of culture, ﬁxed in 3.7%
formaldehyde at room temperature for 10 minutes, and
stained in the dark for 30 minutes in a 0.1M Tris-HCl
solution (pH 8.5) containing 0.2mg/mL of Napthol AS-MX
phosphate and 0.6mg/mL of Fast Blue BB salt (Sigma).
Quantitativereal-timeRT-PCR
The expression of chondrocyte or adipocyte-speciﬁc RNA
markers was analyzed using quantitative real-time RT-PCR.
Total RNA was isolated from cultured growth plate chondro-
cytes using the RNeasy Kit (Qiagen, Valencia, Calif) 4 days
after adenovirus infection or plasmid transfection. Reverse
transcription was performed using random primers and
Superscript III (Invitrogen). Real-time PCR reactions were
conducted in an ABI Prism 7700 Sequence Detection Sys-
tem using SYBR Green PCR core reagents (Applied Biosys-
tems,FosterCity,Calif).ThecomparativeCT method(ΔΔCT
method) was utilized for relative quantitation of gene levels
of expression. 18S rRNA was used as an internal control for
normalization of target gene expression. The forwardand re-


































































Figure 1: Ciglitazone promotes PPARγ expression in the growth plate chondrocytes. Growth plate chondrocytes in pellet cultures were
incubated in the presence or absence of 5μM of ciglitazone for 4 days. (a) Total RNA was collected and real-time PCR was performed
to quantitate PPARγ mRNA levels, which were normalized with respect to endogenous 18S rRNA levels. (b) Proteins were extracted for
immunoblotting to detect PPARγ expression and the immunoblots quantitated using Kodak 1D image analysis software. Actin was used as
an internal control.
Statisticalanalysis
The data for real-time PCR are represented as mean ± stan-
dard deviation. Values are assessed by one-way ANOVA with
the Bonferroni post-hoc test and Student t test at a signiﬁ-




Treatment of growth plate cells with ciglitazone resulted in
increases of both PPARγ mRNA and protein. PPARγ mRNA
wasincreased9-foldafteradditionofciglitazone(5μM)for4
days(Figure 1(a)),whilePPARγ proteinlevelswereincreased
approximately 5-fold (Figure 1(b)).
PPARγ inducesadipogenicdifferentiationin
growthplatechondrocytes
Phase-contrast microscopy demonstrated that the Ad-
PPARγ-infected growth plate chondrocytes acquired the
morphology characteristic of adipocytes after culture in
monolayer for 10 days. Approximately 50% of the cells had
accumulated vacuoles, which were positive for Oil Red-O
staining of lipid accumulation (Figure 2(a)). The control
cellsinfectedwithAd-Gal demonstrated fewOilRed-O posi-
tive vacuoles. Cells treated with 5μM of ciglitazone alone for
Table 1: Primer sequences used for real-time PCR.
Genes Primers
aP2 Forward 5 -GGCTTCGCCACCAGGAA-3 
Reserve 5 -CCCTTCTACGCTGATGATCAAGT-3 
LPL Forward 5 -GGGTCGCCTGGTCGAAGT-3 
Reserve 5 -AAAGTGCCTCCATTGGGATAAA-3  
Adipsin Forward 5 -CCGATGTCCTGCAGCAACT-3 
Reserve 5 -CATGGTACGTGCGCAGATTG-3 
COL2A1 Forward 5 -GGTGGAGCAGCAAGAGCAA-3 
Reserve 5 -CGTCGCCGTAGCTGAAGTG-3 
Aggrecan Forward 5 -CTAGCTGCTTAGCAGGGATAACG-3 
Reserve 5 -CCGCAGAGTCACAAAGACCAA-3 
ALP Forward 5 -GCCGGCAGGACACAGACT-3 
Reserve 5 -GGTTGCAGGGTCTGGAGAGTATA-3 
Runx2/ Forward 5 -TTTAGGGCGCATTCCTCATC-3 
Cbfa1 Reserve 5 -GGAGGGCCGTGGGTTCT-3 
18S Forward 5 -AGTCCCTGCCCTTTGTACACA-3 
Reserve 5 -GATCCGAGGGCCTCACTAAAC-3 
10 days also showed enhanced Oil Red-O staining (20% of
the total cells), while the combination of ciglitazone treat-
ment and Ad-PPARγ infection further enhanced lipid accu-













































Figure 2: Adipogenic changes in the growth plate cells in which PPARγ was overexpressed or cells treated with ciglitazone. (a) Growth plate
cells were infected with Ad-PPARγ or Ad-Gal followed by a 10-day incubation in the presence or absence of ciglitazone (5μM). Cells were
observed under the phase contrast microscope with 10-fold magniﬁcation. Oil Red-O staining shows lipid accumulation within the cells.
(b) Quantitative real-time PCR analysis of the adipogenic marker genes aP2, LPL, and adipsin, in growth plate cells at day 4 of the culture.
Ad-Gal- infected cells were used as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. ∗P<. 05 versus
the expression in control cells.
To characterize the phenotype of the transformed cells
in more detail, the cells were cultured in three-dimensional
cell pellets and the expression of adipocyte diﬀerentiation
marker genes examined by real-time RT-PCR at day 4 of
the culture period. Compared with the control samples,
the levels of expression of the adipogenic marker genes
aP2, LPL,and adipsin increased 6.6-, 4.4- and 4.6-folds, re-
spectively, on day 4 in the 5μM ciglitazone-treated cells
(Figure 2(b)). Expression of aP2, LPL, and adipsin genes in-
creased in the Ad-PPARγ-infected cells by 75.1-, 40.2-, and
76.6-folds, respectively in the absence of ciglitazone, and
101.1-, 44.9-, and 96.3-folds, respectively, in the presence of
ciglitazone (5μM).
In order to address the possibility that PPARγ was act-
ingonanundiﬀerentiatedmesenchymalstemcellasopposed
to a diﬀerentiated chondrocyte, p1757-PPARγ expression
plasmid was generated in which a PPARγ cDNA was placed
under the transcriptional control of the rat COL2A1 gene
promoter and enhancer sequences. Oil Red-O staining of
the p1757-PPARγ-transfected cells maintained in three-
dimensional pellet culture for 10 days showed markedly in-
creased lipid accumulation (Figure 3(a)). Real-time RT-PCR
demonstrated that aP2, LPL, and adipsin mRNA expressions
were upregulated 21.1-, 12.9-, and 17.9-folds, respectively,
compared with the cells transfected with the empty p1757
plasmid at day 4 after transfection (Figure 3(b)).
PPARγ induceslossofchondrocyticphenotype
ingrowthplatecells
Alcian blue staining was used to detect the accumulation of
cartilage-speciﬁc proteoglycan. At day 10, the control cul-
tures of growth plate cells still accumulated abundant pro-
teoglycan (Figure 4(a)). No signiﬁcant diﬀerence in proteo-
glycan accumulation was observed in the growth plate chon-
drocytes that were treated with 5μMo fc i g l i t a z o n ea l o n e .
Compared to the Ad-Gal-infected cells, the Ad-PPARγ-
infected cultures were stained less intensely with Alcian blue,
especially the surrounding of the cells that contained vac-
uoles. Addition of 5μM of ciglitazone to the Ad-PPARγ-
i n f e c t e dc u l t u r e sr e s u l t e di naf u r t h e rd e c r e a s ei np r o t e o g l y -





























Figure 3: Adipogenic changes in the growth plate chondrocytes transfected with a PPARγ plasmid under the control of a collagen α1(II)
promoter. (a) Growth plate cells were transfected with the p1757-PPARγ plasmid. Transfected cells were maintained in pellet cultures for 10
days,followedbyOilRed-Ostaining.(b)QuantitativePCRanalysisofadipogenicmarkersofthep1757-PPARγ transfected growth plate cells
at day 4 after transfection. Cells transfected with the empty p1757 plasmid were used as controls. Gene expression levels were normalized
with respect to endogenous 18S rRNA. ∗P<. 05 versus the expression in control cells.
Quantitative RT-PCR demonstrated that the chondro-
cyte-speciﬁc genes COL2A1 and aggrecan were downregu-
lated by both PPARγ and ciglitazone (Figure 4(b)). Treat-
ment with 5μM of ciglitazone for 4 days resulted in a 33%
decrease of COL2A1 mRNA and a 17% decrease in aggre-
can mRNA expression. Combination of both PPARγ aden-
ovirus and 5μM of ciglitazone resulted in a 50% decrease of




Thyroid hormone is a crucial regulator in growth plate
chondrocyte hypertrophic diﬀerentiation and matrix min-
eralization [15–17]. Growth plate cells treated with thyroid
hormone and 5μM of ciglitazone demonstrated decreased
alkaline phosphatase histochemical staining compared to
cells treated with T3 alone (Figure 5(a)). Quantitative RT-
PCR analysis of growth plate cells in pellet cultures treated
with T3 and 5μM of ciglitazone for 4 days conﬁrmed a
64% decrease in ALP mRNA compared to cells treated with
T3 alone (Figure 5(b)). Infection with PPARγ adenovirus
in cells treated with T3 also decreased expression of ALP
mRNA approximately 71% in the absence of ciglitazone, and
76% in the presence of 5μM of ciglitazone. Runx2/Cbfa1 is
expressed in chondrocytes as they initiate chondrocyte hy-
pertrophy and maturation. Ciglitazone at a concentration
of 5μM decreased the T3-induced expression of Runx2 by
36%.Ad-PPARγ infectiondecreasedtheexpressionofRunx2
mRNA by 54% in the absence of ciglitazone and by 66% in
the presence of 5μM of ciglitazone.
DISCUSSION
Growth plate chondrocytes originate from multipotential
mesenchymal stem cells that can diﬀerentiate into other cell
types including adipocytes. We present evidencein this study
that growth plate cells continue to display diﬀerentiation
plasticity and are able to undergo adipogenic changes and a
reciprocal decrease of chondrocytic markers when PPARγ is
overexpressed.
It has been previously reported that chondrocytes are
able to transdiﬀerentiate into adipocytes in vitro [9]. The
fatty acid content of the serum added to the culture me-
dia has been implicated as a potential cause of this trans-
diﬀerentiation process [6]. We used a serum-free culture sys-
tem in these experiments to avoid the possibility that fatty





































Figure 4: Loss of the chondrogenic phenotype in growth plate cells in which PPARγ was overexpressed or cells treated with ciglitazone. (a)
Growth plate cells were infected with Ad-PPARγ or Ad-Gal followed by a 10-day incubation in the presence or absence of ciglitazone (5μM).
Alcianbluestainingshowstheaccumulationofchondrocyte-speciﬁcmatrix.(b)QuantitativePCRanalysisofchondrogenicgenes,COL2A1,
and aggrecan, in growth plate cells infected with Ad-PPARγ or treated with ciglitazone at day 4 of treatment. Ad-Gal-infected cells were used
as controls. Gene expression levels were normalized with respect to endogenous 18S rRNA. ∗P<. 05 versus the expression in control cells.
Ciglitazone is one of the thiazolidinedione classes of an-
tidiabetic compounds which can activate PPARγ [18]. Cigli-
tazone not only increases endogenous PPARγ transcriptional
activity [11], but also upregulates PPARγ mRNA and protein
expression in growth plate chondrocytes, as observed in this
study.
Activation of endogenous PPARγ by ciglitazone or aden-
oviraloverexpressionofPPARγ ingrowthplatechondrocytes
resulted in acquisition of adipogenic features in both high-
densitymonolayerculturesandthree-dimensionalpelletcul-
turesofgrowthplatechondrocytes,asevidencedbycellmor-
phology, lipid accumulation, and expression of adipocyte
markergenesaP2,LPL,andadipsin.Growthplatecellsmain-
tained in monolayer cultures seemed to acquire features of
the adipocytic phenotype and lose features of the chondro-
cyticphenotypemorereadilythanthoseinthepelletcultures
(data not shown).
To conﬁrm that the adipocyte-like cells were diﬀerenti-
ateddirectlyfromchondrocytesandnotfromothercelltypes
such as undiﬀerentiated mesenchymal stem cells, growth
plate cells were transfected with a PPARγ plasmid under the
c o n t r o lo fac o l l a g e nα1(II) promoter. Acquisition of the adi-
pogenic phenotype in these transfected cells was similar to
the cells infected with an adenovirus encoding PPARγ and
driven by the CMV promoter/enhancer.
While PPARγ andciglitazoneconvertedcellsofthechon-
drocyte lineage to an adipocytic phenotype, features of
the chondrocyte phenotype were simultaneously suppressed.
PPARγ inhibited the ability of chondrocytes to terminally
diﬀerentiate into hypertrophic cells, and suppressed the ex-
pression of genes encoding chondrocyte-speciﬁc extracellu-
lar matrix proteins.
Slipped capital femoral epiphysis (SCFE) is an obesity-
related hip disease in children characterized by weakness
in the growth plate of the proximal femur, delayed skele-
tal maturation, and eventual mechanical failure of the ph-
ysis [19–21]. We speculate that obesity may induce the ex-
pression of PPARγ isoforms in growth plate chondrocytes,
resulting in phenotypic changes that interrupt normal skele-
tal maturation at the growth plate through interference with
thyroid hormone signaling. This interference with thyroid
hormone-mediated terminal diﬀerentiation of growth plate
cells and resulting decreased mineralization of the cartilage
matrix would be expected to reduce the resistance of the
growth plate to shear stresses. Therefore this delay in matu-
ration at the growth plate, combined with both the increased
mechanical stress resulting from increased body weight and
the decreased shear stress resulting from delayed matura-
tion, may combine to cause the proximal femoral epiphysis




































Figure 5: Inhibition of T3-induced hypertrophy and mineraliza-
tion in the growth plate cells by PPARγ overexpression or cigli-
tazone treatment. (a) Growth plate cells were treated with T3
(100ng/mL) in the presence or absence of ciglitazone (5μM) for
10 days. Alkaline phosphatase (ALP) staining was used as a marker
of terminal diﬀerentiation of growth plate chondrocytes. Positive
stainings were colored in dark blue. Negative-stained background
was colored in light green. (b) Quantitative PCR analysis of ALP
and Runx2 genes 4 days after growth plate cells were infected with
Ad-PPARγ or treated with ciglitazone. Ad-Gal-infected cells with-
out T3 or ciglitazone treatment were used as controls. Gene expres-
sion levels were normalized with respect to endogenous 18S rRNA.
∗P<. 05 versus the expression in the Ad-Gal-infected cells with T3-
treatment.
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